Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors

NCT06084416 is registered in ClinicalTrials.gov with Volastra Therapeutics, Inc. as lead sponsor.

NCT NCT06084416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06084416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors
Lead sponsor
Volastra Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 4, 2024
Completion date
December 31, 2027
Enrollment
150 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chromosomal instability, fallopian tube cancer, high grade serous adenocarcinoma of ovary, primary peritoneal carcinoma